Laboratory experiments in human bronchial epithelial cells show that dual-corrector drug combinations can rescue both processing and chloride channel function in an ultra-rare cystic fibrosis CFTR variant, F1078S. The study’s core contribution is functional: it reports restoration of CFTR activity rather than only improved protein expression. That distinction matters for ultra-rare genotypes, where patient-level clinical evidence is often limited. If the combination strategy progresses, it could inform individualized treatment development for patients whose genotypes currently lack robust evidence for existing CFTR modulators.